Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine vs Observation in HER2+ Breast Cancer with Residual Disease
NCT03684863Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Oct 2018
- Primary completion
- Dec 2023
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
01
Overview
A Phase 2 trial of capecitabine in HER2-positive breast cancer, sponsored by Shandong Cancer Hospital. Planned start Oct 2018; status: not yet recruiting.
02
Drugs
capecitabine
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT03684863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03684863.